Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled WEgovy Real ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Imagine this scenario: You’ve been diligently working toward your weight management goals, and your healthcare team has prescribed Wegovy (semaglutide). You’re excited, you’ve done your research, and ...

If you’re exploring diabetes or weight-loss medications, Ozempic and Wegovy have become two popular options of injectable treatments. Both medications support blood sugar control and weight loss, but ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

"In the SURMOUNT-5 trial, Zepbound demonstrated a significantly higher magnitude of weight reduction compared to Wegovy across all comparisons," said Leonard Glass, MD, FACE, senior vice president, ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...